BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for…


Previous articlePsychedelic Bulletin: UCSF Launches Psychedelics Division; New Additions to the Psychedelics ETF; Massachusetts City Decriminalizes Psychedelics
Next articlePT238 – Kile Ortigo – Integration and Existential Exploration